此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Implementing Genomics in Practice (IGNITE) Proof of Concept Study: Genotyping in Family Medicine Clinics (IGNITE)

2019年6月5日 更新者:University of Florida
This study will examine the effect of having genotype information on pain management and pain control for patients treated in family medicine clinics. This study will also examine physician-perceived usefulness of genotype information. Patients will be enrolled from family medicine clinics serving as either implementation sites or control sites. Patients from implementation sites will undergo genotyping, while those from control sites will not by genotyped.

研究概览

详细说明

Codeine and tramadol are opioid analgesics that depend on cytochrome P450 2D6 (CYP2D6) for bioactivation to morphine and O-desmethyltramadol, respectively. Morphine and O-desmethyltramadol have much greater affinity for the opioid receptor and thus are more powerful analgesics.

Individuals with genotypes associated with low CYP2D6 activity (poor metabolizers) are unable to convert sufficient amounts of codeine or tramadol to their active metabolites and may fail to derive sufficient pain relief. At the opposite extreme, individuals with genotypes associated with increased CYP2D6 activity (ultra-rapid metabolizers) are at risk for serious toxicity with usual codeine or tramadol doses.

The CYP2D6 genotype also has implications for response to other drugs, such as tricyclic antidepressants (TCAs), which are commonly used for neuropathic pain.

Patients will be recruited from family medicine clinics, serving as either implementation sites or control sites. Patients from implementation sites will undergo CYP2D6 genotyping, with results placed in the medical record to assist with prescribing of pain medications. Pain medications prescribed from baseline to 3 months will be assessed through medical record review. A pain assessment questionnaire will be administered to patients enrolled from both sites at baseline and 3 months.

At the end of the study, a 20-item survey will be administered to physicians at the implementation sites. We will assess whether having CYP2D6 genotype results is useful to inform prescribing decisions for pain medication from the physician's perspective.

We will also assess medicines prescribed to patients enrolled from both sites over the 12-month period after enrollment from medical record review and determine the number of patients who were prescribed a medication that has genetic information in its FDA-approved label.

研究类型

观察性的

注册 (实际的)

505

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Florida
      • Archer、Florida、美国、32618
        • Archer Family Health Care
      • Gainesville、Florida、美国、32606
        • UF Health Spring Hill Pain Management
      • Gainesville、Florida、美国、32607
        • UF Health Family Medicine: Hampton Oaks
      • Gainesville、Florida、美国、32607
        • UF Health Internal Medicine - Tower Hill
      • Gainesville、Florida、美国、32608
        • UF Health Family Medicine: Haile Plantation
      • Gainesville、Florida、美国、32609'
        • UF Health Family Medicine: Main Street
      • Gainesville、Florida、美国、32610
        • UF Health Internal Medicine-Medical Plaza
      • Gainesville、Florida、美国、32641
        • UF Health Family Medicine: Eastside
      • Old Town、Florida、美国、32680
        • UF Health Family Medicine - Old Town
      • Oviedo、Florida、美国、32765
        • Oviedo Family Health Center
      • Saint Cloud、Florida、美国、34769
        • ProHealth Family Physicians

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 80年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Patients will be enrolled from family medicine clinics serving as either implementation sites or control sites for pain mangement.

描述

Inclusion Criteria:

  • Treated in family medicine clinic
  • History of pain for at least 3 months
  • Prescribed medication for pain relief

Exclusion Criteria:

  • Pain for less than 3 months
  • Not currently prescribed any medication for pain

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
干预/治疗
Control
Patients will continue to receive their current pain management therapy. In addition, a pain assessment questionnaire will be administered at baseline and 3 months.
A pain assessment questionnaire will be administered at baseline and 3 months.
其他名称:
  • PROMIS questionnaire
Implementation
Patients will undergo CYP2D6 genotyping, with results entered into the medical record to assist the physician with prescribing pain medication. In addition, a pain assessment questionnaire will be administered at baseline and 3 months.
A pain assessment questionnaire will be administered at baseline and 3 months.
其他名称:
  • PROMIS questionnaire
CYP2D6 genotype results and an interpretive report will be placed in the electronic medical record to assist the physician with prescribing medication for pain management.
Physician assessment
At the end of the study, a 20-item survey will be administered to physicians who treated patients enrolled in the study. The survey will assess whether having CYP2D6 genotype results is useful to inform prescribing decisions for pain medication from the physician's perspective.
20-item survey administered to physicians treating patients enrolled in the study

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in overall pain score (Patient Reported Outcomes Measurement Information System (PROMIS)
大体时间:Change from baseline to 3 months
Patient Reported Outcomes Measurement Information System (PROMIS) measures will be used to assess pain intensity, physical functioning, and emotional functioning. There are 10 subscales on the PROMIS questionnaire that address the domains of pain, pain functioning, and emotional functioning. At least 4 (and up to 30) items are used to derive a score for each subscale. A computer adaptive version of the questionnaire based on item response theory will be used to administer the survey. A score of 0 to 100 based on survey responses will be resulted for each subscale.
Change from baseline to 3 months

次要结果测量

结果测量
措施说明
大体时间
Change in pain medication
大体时间:Change from baseline to 3 months
Change in pain medication will be evaluated in several manners: change in the opiate prescribed, change from an opiate to a non-opiate; and change in dose of the opiate prescribed
Change from baseline to 3 months
Change in pain score of pain intensity (Patient Reported Outcomes Measurement Information System (PROMIS) subscale)
大体时间:Change from baseline to 3 months
Patient Reported Outcomes Measurement Information System (PROMIS) subscale for pain intensity, with the score ranging from 0 to 100 resulting.
Change from baseline to 3 months
Change in pain score of physical functioning (Patient Reported Outcomes Measurement Information System (PROMIS) subscale)
大体时间:Change from baseline to 3 months
Patient Reported Outcomes Measurement Information System (PROMIS) subscales for physical functioning include pain function, pain interference, pain behavior, sleep disturbance, and sleep-related impairment. A score of 0 to 100 based on survey responses will be resulted for each subscale.
Change from baseline to 3 months
Change in pain score of emotional functioning
大体时间:Change from baseline to 3 months
Patient Reported Outcomes Measurement Information System (PROMIS) subscales for emotional functioning include fatigue, anxiety, depression, and anger. A score of 0 to 100 based on survey responses will be resulted for each subscale.
Change from baseline to 3 months
Physician perceived usefulness of genetic information (survey)
大体时间:3 months
Survey will be administered to physicians with patients in the study to assess the effect of having genotype information on their prescribing decisions.
3 months
Medications prescribed with pharmacogenetic implications (Percent of patients with at least one other drug (besides an opioid) where genotype information might be useful for prescribing)
大体时间:12 months
Percent of patients with at least one other drug (besides an opioid) where genotype information might be useful for prescribing
12 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Larisa Cavallari, PharmD、University of Florida

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2015年6月1日

初级完成 (实际的)

2017年6月12日

研究完成 (实际的)

2017年10月25日

研究注册日期

首次提交

2015年1月7日

首先提交符合 QC 标准的

2015年1月8日

首次发布 (估计)

2015年1月9日

研究记录更新

最后更新发布 (实际的)

2019年6月6日

上次提交的符合 QC 标准的更新

2019年6月5日

最后验证

2019年6月1日

更多信息

与本研究相关的术语

关键字

其他研究编号

  • IRB201400501 - N
  • U01HG007269-02 (美国 NIH 拨款/合同)
  • OCR14741 (其他标识符:Universiy of Florida)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

The consent form has an addendum for NIH dbGaP. Participants who agree will have their deidentified results shared to dbGaP. Those who do not agree will not have their results shared.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅